---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-22-031808"
form_type: "8-K"
ticker: "GRI"
cik: "0001824293"
company_name: "GRI Bio, Inc."
filed_at: "2022-12-13T23:59:59+00:00"
generated_at: "2026-06-21T05:37:48.555912+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Vallon Pharmaceuticals to merge with GRI Bio in reverse merger; GRI shareholders to own 83-96.7% of combined company

## Summary
- Reverse merger: Vallon Merger Sub merges into GRI; GRI survives as wholly owned subsidiary of Vallon.
- Post-closing, GRI shareholders expected to own 83.0% to 96.7% of Vallon; Marc Hertz (GRI CEO) to become CEO.
- Pre-merger financing: $3.3M bridge notes (Altium) convertible to ~$2.5M cash; $12.25M equity investment at close.
- Lock-up agreements for 90 days after earliest of Rule 144 eligibility or one-year anniversary; termination fee $2M.

## SEC filing metadata
- accession: 0001628280-22-031808
- form_type: 8-K
- ticker: GRI
- cik: 0001824293
- company_name: GRI Bio, Inc.
- filed_at: 2022-12-13T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1824293/000162828022031808/0001628280-22-031808-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1824293/000162828022031808/val-20221213.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-22-031808
- JSON: https://secwatch.observer/filing/0001628280-22-031808.json
- Plain text: https://secwatch.observer/filing/0001628280-22-031808.txt

## Key facts
- Material Agreements
  GRI Bio, Inc. entered into Agreement and Plan of Merger with GRI Bio, Inc. and Vallon Merger Sub, Inc. (effective 2022-12-13).
  - Action: entry
  - Agreement: merger
  - Counterparty: GRI Bio, Inc. and Vallon Merger Sub, Inc.
  - Effective: 2022-12-13
  source text: On December 13, 2022, Vallon Pharmaceuticals, Inc. (“Vallon”) entered into an Agreement and Plan of Merger (the “Merger Agreement”) with GRI Bio, Inc., a Delaware corporation (“GRI”), and Vallon Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Vallon (“Merger Sub”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1824293/000162828022031808/0001628280-22-031808-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.